Prevalence and healthcare utilization in managing herpes zoster in primary care: a retrospective study in an Asian urban population

Xin-Bei Valerie Chan, Ngiap Chuan Tan, Mark Ng, Ding Xuan Ng, Yi Ling Eileen Koh, Wai Keong Aau, Chirk Jenn NgFrontiers in Public Health 2023 · DOI

TL;DR

This retrospective study quantifies the burden of herpes zoster (shingles) across eight public primary care clinics in Singapore, revealing a mean annual prevalence of 216 per 100,000 persons that peaks sharply in the 70–79 age group. The findings highlight a significant reliance on primary care for management, a surprising prevalence of topical antiviral prescriptions despite limited clinical evidence, and specific chronic conditions like asthma and hypertension as key risk factors.

What Problem Does This Paper Address?

Herpes zoster (HZ), caused by the reactivation of the varicella-zoster virus, leads to painful rashes and potentially debilitating complications like post-herpetic neuralgia. While a highly effective recombinant zoster vaccine (RZV) exists, it is not yet part of Singapore’s National Adult Immunization Schedule.

To inform public health policy and clinical guidelines, researchers need localized data on how HZ affects the population and how much it strains the healthcare system. Most existing studies focus on tertiary (hospital) settings, leaving a "knowledge gap" regarding HZ management in primary care—where the vast majority of cases are actually treated. This paper seeks to fill that gap by analyzing prevalence, risk factors, and healthcare utilization in an urban Asian context.

Methods

The authors conducted a retrospective database review using the SingHealth-IHiS Electronic Health Intelligence System (eHints). This repository integrates administrative and clinical data from a cluster of eight public polyclinics in Singapore.

  • Study Period: January 2018 to December 2020.
  • Population: All individuals aged 21 and above who visited these clinics.
  • Analysis: The team used Pearson’s chi-square tests and multivariate logistic regression to calculate adjusted odds ratios (aOR) for various risk factors, including age, ethnicity, and 22 different chronic conditions.

Datasets

The study utilized the eHints database, a large-scale real-world dataset.

  • Total Population Screened: 737,868 individuals.
  • HZ Cases Identified: 2,987 unique patients.
  • Data Points: Socio-demographics, ICD-10 diagnosis codes, prescriptions, medical leave (absenteeism), and electronic referral records.

Key Insights and Ideas

  • The Age Peak: While HZ risk is known to increase after 50, this study found the highest prevalence (829 per 100,000) specifically in the 70–79 age group. This suggests that vaccination efforts should be aggressively targeted at this cohort.
  • The "Topical Acyclovir" Disconnect: Nearly half (47.6%) of patients were prescribed topical acyclovir. The authors point out that clinical guidelines generally do not recommend topical antivirals because they lack efficacy in treating HZ. This highlights a gap between evidence-based guidelines and real-world prescribing habits, possibly driven by patient requests.
  • The Chronic Disease Paradox: While asthma, hypertension, and osteoarthritis were associated with increased HZ risk, Diabetes and Chronic Kidney Disease (CKD) showed a negative association (lower risk). The authors hypothesize this might be due to "surveillance bias"—these patients see doctors more frequently for their chronic conditions, providing more opportunities for early intervention or vaccination.
  • COVID-19 Impact: There was a slight dip in HZ prevalence in 2020. The researchers suggest that pandemic measures (masking, social distancing) reduced the prevalence of other respiratory viruses that typically act as "triggers" for HZ reactivation.

Key Results

  • Prevalence: The mean yearly prevalence was 216 per 100,000 persons.
  • Management: 91.1% of cases were managed entirely within primary care. Most patients (84.3%) required only a single consultation.
  • Treatment: Oral acyclovir was the standard (71.6%), with a median daily dose of 4,000 mg for 7 days. Gabapentin was the most common analgesia (41.0%).
  • Referrals: Only 8.9% of cases required hospital referral, primarily to emergency departments or ophthalmology (often for suspected herpes zoster ophthalmicus, which threatens vision).
  • Productivity Loss: 32.7% of patients required medical leave, with a median duration of 5 days.

Limitations and Future Work

The study has a few notable limitations:

  1. Public vs. Private: The data only covers public polyclinics. Patients seeking care at private GPs or those who self-medicated were not captured, likely leading to an underestimation of the total HZ burden.
  2. Clinical Detail: As a retrospective database study, the researchers couldn't determine the exact duration from symptom onset to the first clinic visit, which heavily influences the effectiveness of antiviral therapy.
  3. Recurrence: The study assumed HZ visits within a certain timeframe belonged to a single episode, potentially missing rare cases of recurrent HZ.

Future Work: The authors call for research into the underlying reasons for the high use of topical acyclovir and further exploration into the efficacy of combination analgesia for HZ-related pain management.

Summary updated

Abstract

Herpes zoster (HZ) causes significant morbidity, particularly in older adults. With the advent of a recombinant zoster vaccine, HZ is potentially preventable. However, data on HZ burden and healthcare utilization in primary care populations remains scarce. This study described the prevalence and healthcare utilization in managing HZ in a developed community. A retrospective database review was conducted across a cluster of 8 public primary care clinics in urban Singapore. Data of multi-ethnic Asian patients with a diagnosis code of "herpes zoster" from 2018 to 2020 was extracted from their electronic medical records. Socio-demographic, clinical, visitation, medical leave, prescription, and referral data were analyzed. A total of 2,987 out of 737,868 individuals were diagnosed with HZ over 3 years. The mean age was 59.9 (SD + 15.5) years; 49.2% were male; 78.5% Chinese, 12.2% Malay, and 4.1% Indian. The prevalence was 221, 224, 203 per 100,000 persons in 2018, 2019, and 2020, respectively. The 70 to 79-year age group had the highest prevalence (829/100,000) across 3 years. Oral acyclovir (median daily dose 4,000 mg; median duration 7 days) and topical acyclovir were prescribed in 71.6 and 47.6%, respectively. Analgesia prescribed were gabapentin (41.0%), paracetamol combinations (30.1%), oral NSAIDs (23.7%), opioids (6.0%), and tricyclic antidepressants (1.9%). Most individuals consulted only once (84.3%); 32.7% of them required medical leave and 5.6% had more than 7 days of absenteeism. HZ-related referrals to the hospital were required in 8.9% (4.9% emergency, 2.8% ophthalmology). The findings of this study suggest a need for HZ vaccination among older age groups. Visitation and referral rates were low. The use of topical acyclovir was uncovered, and further research should evaluate the underlying reasons, benefits, and harms of such practice. The use of analgesia combinations may be explored further.
BibTeX
@inproceedings{chan2023prevalence,
  author = {Xin-Bei Valerie Chan and Ngiap Chuan Tan and Mark Ng and Ding Xuan Ng and Yi Ling Eileen Koh and Wai Keong Aau and Chirk Jenn Ng},
  title = {{Prevalence and healthcare utilization in managing herpes zoster in primary care: a retrospective study in an Asian urban population}},
  booktitle = {Frontiers in Public Health},
  year = {2023},
  doi = {10.3389/fpubh.2023.1213736},
}
Figure